💸 The Tape

TerrAscend reported third-quarter results that look, on the surface, like a company doing exactly what it said it would do. Revenue rose 4.8% to $68.2 million, gross margin held above 52%, adjusted EBITDA came in at $17.5 million on a 25.6% margin, and the company logged its 13th consecutive quarter of positive free cash flow. Jason Wild’s quote was a single sentence about “driving top-tier adjusted EBITDA margins,” which is the kind of thing an executive chairman says when the quarter is unremarkable in the good sense.

Then you get to the balance sheet, where the uncertain tax position liability jumped to $163.5 million from $128.8 million at year-end, a $35 million increase in nine months. That’s now larger than TerrAscend’s cash, roughly three-quarters the size of its debt, and depending on the day, close to the company’s entire equity value. It’s also the single most important number in the release, because it determines whether TerrAscend is a buyer, a seller or a bystander in the consolidation everyone expects once Schedule III settles.

The operating story

Start with what’s working. Pennsylvania grew 16.8% year over year with 12% same-store sales growth and a 31% increase in wholesale revenue, and five of the company’s six Apothecarium stores rank among the state’s top 15 by sales. That’s a capped market where TerrAscend is extracting more from the same footprint, which is the only growth available to anyone there. New Jersey held its leading position and gained share while launching The One and Cuue brands, and the September close of Aunt Mary’s in Flemington adds more than $10 million in annualized revenue and a fifth dispensary against the state’s cap. Maryland grew sequentially and year over year.

Gross margin at 52.3% remains the best among mid-cap MSOs, a function of a wholesale-weighted model in high-price Northeast markets. EBITDA on a GAAP basis rose to $20.2 million from $14.3 million. The net loss from continuing operations narrowed to $5.5 million from $9.9 million, and total net loss collapsed from $24.6 million to $5.5 million because the Michigan business is now discontinued, generating $0.8 million of income for the nine months against a $61 million loss last year. The Michigan exit removed the one market that was destroying value, and the comparables show it.

Operating cash flow from continuing operations was $8.8 million, free cash flow $6.1 million after $2.7 million of capex. Cash rose to $42.5 million from $37.4 million at year-end, which is progress but not much of it for a company that’s been cash-flow positive for 17 straight quarters. The reason sits in the next paragraph.

What’s not working

Income tax expense was $11.9 million for the quarter and $33.7 million for nine months, which means TerrAscend is accruing taxes at roughly 17% of revenue and paying a fraction of it in cash. That’s the 280E position in action: the company, like Jushi and several peers, has taken the stance that it owes less than the IRS calculates, books the difference as an uncertain tax position, and lets the liability grow. The liability grew $34.7 million in nine months while cash grew $5.1 million. Any reading of TerrAscend’s “positive free cash flow” has to account for the fact that a meaningful share of it is tax the company has decided not to remit.

Debt stands at roughly $217 million including $18.3 million of convertibles, little changed from year-end. Net debt to annualized adjusted EBITDA is about 2.5x. The company renewed its buyback for up to $10 million and repurchased just over a million shares year-to-date, which at current prices is immaterial.

The uplisting question

Shareholders approved a share consolidation in August “as preparation for a potential listing on a major U.S. exchange,” and the release restates that intention without a timeline. The Trulieve template is clear: NYSE listing requires a medical-only or otherwise compliant structure, and TerrAscend is a mixed-use operator in New Jersey, Maryland and Ohio with medical in Pennsylvania. Absent full Schedule III, an uplisting means some version of the Harvest-style deconsolidation, and with a $163.5 million tax contingency on the books, the entity that gets listed will have to explain how it’s handled.

That’s the strategic bind. TerrAscend’s operating assets, particularly New Jersey and Pennsylvania, are the kind that Cresco or Green Thumb would want. The uncertain tax position is the kind of liability that complicates any deal, because an acquirer either assumes it, negotiates it out of the price or waits for the IRS to settle it. Full rescheduling would resolve much of this. The DEA stay expired today, and Judge Julius’s recommendation is the next event. TerrAscend has more riding on that document than almost any operator its size.

📈 Dog Walkers

$CRON ( ▲ 5.98% ) Reports Q3

Cronos Group is now the fastest-growing cannabis company of any size, and it’s doing it without acquisitions. Net revenue rose 75% to $63.5 million, up 73% on an organic, constant-currency basis, and the company posted records in revenue, gross profit and adjusted EBITDA for the second consecutive quarter. Adjusted EBITDA tripled to $17.1 million. Gross margin held above 50%. Nine-month operating cash flow was $69.2 million, up from $14 million a year ago.

The engine is international flower. Revenue outside Israel and Canada rose 614%, led by Germany, where medical flower demand has outstripped supply since the 2024 reform. Israel delivered its eleventh consecutive record quarter, up 33%. Canada posted record revenue too, with Spinach holding #2 overall at 6.3% share, #1 in edibles for the ninth straight quarter at 21.8%, and #1 in vapes at 11.4%. That’s a domestic brand portfolio funding an export business with pricing power Canada hasn’t seen in years.

Mike Gorenstein’s quote is the one investors should read twice: Cronos “organically achieved records” and “maintains an industry-leading balance sheet.” That’s $840.6 million in cash, short-term investments and deposits, with no debt, in a company whose market cap has hovered around $1 billion for most of the year. Cronos is trading at less than two times its cash, and it’s generating cash.

It’s also deploying it, carefully. The CanAdelaar acquisition closed in October, giving Cronos a cultivation position in the Dutch adult-use pilot, which Gorenstein calls “Europe’s largest adult-use cannabis market.” Cronos took majority board control of GrowCo, which just completed a cultivation expansion, locking in the supply it needs for Germany. And it bought back 15.5 million shares for $42.3 million year-to-date.

The gaps: net income fell 37% to $17.8 million, mostly on non-operating items; no Q3-only cash flow figure; and the adjusted EBITDA definition changed this quarter to exclude GIC credit-loss provisions, which is the kind of tweak worth watching. Altria still owns roughly 40%, which caps the float and the upside.

But the core observation is simple. Cronos is the only Canadian LP with real growth, real margins, no debt and more cash than most of its peers combined. In a week when Organigram needed BAT’s money to buy Aurora, Cronos could have written the check from its checking account.

📺 Trade To Black

Can Organigram Hold Off Curaleaf Plus Who Won Earnings Season? | TTB Presented by Flowhub

• Organigram CEO James Yamanaka joins the show to walk through the C$7.80-per-share, C$561M deal for Aurora, a 93% premium to the pre-Curaleaf price and 21% above the hostile bid, with BAT putting in C$187.5M and voting in favor. What’s the path to close while Curaleaf’s offer is still on the table?

• NewLake CEO Anthony Coniglio breaks down a quarter of 99.7% rent collection, zero debt after repaying the final $7.6M, $17.9M in cash and $12.0M in revenue.

• FundCanna’s Adam Stettner reviews a packed week of earnings: Green Thumb’s $324.4M in revenue, up 11.3%, Trulieve’s 39% adjusted EBITDA margin and final DEA registrations, and Aurora’s record international medical revenue, up 44%.

• The through-line: consolidation is here, and Stettner lays out what growth, margins and cash flow are telling investors about who’s positioned for it.